Cargando…
Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs). As a new alternative treatment modality, immunological approaches using monoc...
Autores principales: | Harada, Takeshi, Ozaki, Shuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124849/ https://www.ncbi.nlm.nih.gov/pubmed/25143955 http://dx.doi.org/10.1155/2014/965384 |
Ejemplares similares
-
The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells
por: Staudinger, M, et al.
Publicado: (2014) -
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
por: Harada, Takeshi, et al.
Publicado: (2013) -
HM1.24/BST-2 is constitutively poly-ubiquitinated at the N-terminal amino acid in the cytoplasmic domain
por: Fujimoto, Keiko, et al.
Publicado: (2020) -
CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
por: Gross Even-Zohar, Noa, et al.
Publicado: (2022) -
The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression
por: Gilad, Nechama, et al.
Publicado: (2019)